TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: tscan.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $12.00 | Buy | BTIG Research |
| 5/13/2024 | $11.00 | Buy | Needham |
| 6/22/2023 | $8.00 | Outperform | Wedbush |
| 12/16/2021 | $21.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | Outperform | Cowen & Co. | |
| 8/10/2021 | $22.00 | Overweight | Barclays |
| 8/10/2021 | $22.00 | Overweight | Morgan Stanley |
| 8/10/2021 | $21.00 | Buy | Jefferies |
SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
DEFA14A - TScan Therapeutics, Inc. (0001783328) (Filer)
DEF 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
EFFECT - TScan Therapeutics, Inc. (0001783328) (Filer)
S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)
S-3 - TScan Therapeutics, Inc. (0001783328) (Filer)
10-K - TScan Therapeutics, Inc. (0001783328) (Filer)